|  |
Feb 2003 Stock Report
|
|
02/28/03 Close
|
% 52wk High
|
% change from 02/28/02
|
Market Cap ($M)
|
Cash & Mkt. Sec. ($M)
|
Tech Value ($M)
|
LT Debt plus Convert
|
# of Staff
|
Tech Value / Staff ($M)
|
Est. Burn Rate ($M)
|
Survival Index (Yrs)
|
Equity Multiple
|
| GENOME THERAPEUTICS CORP |
$1.73 |
28% |
-66% |
$ 40 |
$54 |
-$14 |
$16 |
176 |
-$0.1 |
-$40.3 |
1.3 |
0.9 |
| HUMAN GENOME SCIENCES |
$6.79 |
26% |
-67% |
$874 |
$1,352 |
-$478 |
$503 |
1010 |
-$0.5 |
-$300.3 |
4.5 |
0.5 |
| INCYTE GENOMICS |
$3.38 |
26% |
-69% |
$230 |
$453 |
-$223 |
$172 |
585 |
-$0.4 |
-$153.6 |
2.9 |
0.3 |
| MILLENNIUM PHARMACEUTICALS |
$7.16 |
28% |
-62% |
$2,055 |
$1,822 |
$233 |
$83 |
1900 |
$0.1 |
na |
na |
0.5 |
| MYRIAD GENETICS |
$9.78 |
26% |
-70% |
$264 |
$59 |
$206 |
$0 |
491 |
$0.4 |
-$21.3 |
2.8 |
1.3 |
| 1st Generation Genomics Average |
. |
27% |
-67% |
$693 |
$748 |
-$55 |
$155 |
. |
-$0.1 |
-$128.9 |
2.9 |
0.7 |
| 1st Generation Genomics Median |
. |
27% |
-67% |
$247 |
$256 |
-$6 |
$50 |
. |
$0.0 |
-$40.3 |
2.8 |
0.7 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
02/28/03 Close
|
% 52wk High
|
% change from 02/28/02
|
Market Cap ($M)
|
Cash & Mkt. Sec. ($M)
|
Tech Value ($M)
|
LT Debt plus Convert
|
# of Staff
|
Tech Value / Staff ($M)
|
Est. Burn Rate ($M)
|
Survival Index (Yrs)
|
Equity Multiple
|
| ACLARA BIOSCIENCES |
$2.00 |
52% |
-44% |
$ 72 |
$119 |
-$47 |
$1 |
170 |
-$0.3 |
-$44.8 |
2.7 |
0.3 |
| AFFYMETRIX |
$26.39 |
85% |
7% |
$1,541 |
$353 |
$1,188 |
$370 |
905 |
$1.3 |
na |
na |
4.4 |
| CALIPER TECHNOLOGIES |
$3.26 |
23% |
-70% |
$80 |
$128 |
-$48 |
$0 |
132 |
-$0.4 |
-$37.5 |
3.4 |
0.3 |
| CELERA GENOMICS GROUP |
$8.25 |
35% |
-59% |
$590 |
$880 |
-$290 |
$0 |
na |
na |
na |
na |
na |
| CEPHEID |
$3.98 |
60% |
49% |
$123 |
$21 |
$102 |
$2 |
143 |
$0.7 |
-$23.0 |
0.9 |
1.5 |
| CIPHERGEN BIOSYSTEMS |
$5.00 |
69% |
-13% |
$136 |
$46 |
$91 |
$0 |
229 |
$0.4 |
-$31.6 |
1.4 |
0.8 |
| COMBIMATRIX |
$2.05 |
41% |
na |
$ 39 |
na |
na |
na |
na |
na |
na |
na |
na |
| ILLUMINA |
$2.41 |
25% |
-65% |
$ 78 |
$ 0 |
$78 |
$0 |
179 |
$0.4 |
-$30.4 |
0.0 |
na |
| SEQUENOM |
$1.68 |
22% |
-70% |
$ 66 |
$106 |
-$40 |
$6 |
272 |
-$0.1 |
-$68.0 |
1.6 |
0.1 |
| TRANSGENOMIC |
$1.93 |
21% |
-76% |
$ 45 |
$18 |
$27 |
$0 |
na |
na |
-$18.9 |
1.0 |
0.4 |
| Genomic Supply Average |
. |
43% |
-38% |
$277 |
$186 |
$118 |
$42 |
. |
$0.3 |
-$36.3 |
1.6 |
1.1 |
| Genomic Supply Median |
. |
41% |
-52% |
$ 78 |
$76 |
$14 |
$0 |
. |
$0.4 |
-$31.0 |
1.2 |
0.6 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
02/28/03 Close
|
% 52wk High
|
% change from 02/28/02
|
Market Cap ($M)
|
Cash & Mkt. Sec. ($M)
|
Tech Value ($M)
|
LT Debt plus Convert
|
# of Staff
|
Tech Value / Staff ($M)
|
Est. Burn Rate ($M)
|
Survival Index (Yrs)
|
Equity Multiple
|
| APPLIED MOLECULAR EVOLUTION |
$2.49 |
28% |
-71% |
$ 51 |
$55 |
-$4 |
$10 |
83 |
$0.0 |
-$20.4 |
2.7 |
0.3 |
| ARENA PHARMACEUTICALS |
$6.50 |
61% |
-33% |
$180 |
$196 |
-$16 |
$0 |
209 |
-$0.1 |
-$41.1 |
4.8 |
0.6 |
| CURAGEN CORP |
$3.43 |
19% |
-79% |
$169 |
$431 |
-$262 |
$150 |
454 |
-$0.6 |
-$79.5 |
5.4 |
0.3 |
| DECODE GENETICS |
$2.01 |
31% |
-66% |
$108 |
$102 |
$6 |
$0 |
592 |
$0.0 |
-$86.8 |
1.2 |
0.2 |
| DELTAGEN |
$0.25 |
3% |
-97% |
$10 |
$50 |
-$39 |
$2 |
356 |
-$0.1 |
-$85.2 |
0.6 |
0.0 |
| EXELIXIS |
$5.77 |
39% |
-49% |
$331 |
$154 |
$177 |
$0 |
571 |
$0.3 |
-$91.8 |
1.7 |
0.7 |
| GENE LOGIC |
$5.05 |
25% |
-69% |
$137 |
$172 |
-$35 |
$1 |
272 |
-$0.1 |
-$27.8 |
6.2 |
0.4 |
| GENENCOR INTERNATIONAL |
$9.72 |
77% |
-5% |
$567 |
$171 |
$396 |
$85 |
1144 |
$0.3 |
na |
na |
1.1 |
| LARGE SCALE BIOLOGY |
$0.57 |
15% |
-80% |
$ 14 |
$27 |
-$13 |
$0 |
169 |
-$0.1 |
-$27.1 |
1.0 |
0.1 |
| LEXICON GENETICS |
$3.85 |
40% |
-54% |
$202 |
$114 |
$88 |
$0 |
507 |
$0.2 |
-$67.2 |
1.7 |
0.6 |
| LYNX THERAPEUTICS |
$2.15 |
11% |
-88% |
$ 9 |
$13 |
-$3 |
$1 |
182 |
$0.0 |
-$13.1 |
1.0 |
0.1 |
| MAXYGEN |
$7.36 |
55% |
-41% |
$253 |
$229 |
$25 |
$0 |
308 |
$0.1 |
-$29.2 |
7.8 |
0.6 |
| NANOGEN |
$1.07 |
21% |
-74% |
$ 23 |
$46 |
-$23 |
$0 |
194 |
-$0.1 |
-$32.9 |
1.4 |
0.1 |
| NUVELO |
$0.80 |
12% |
-85% |
$18 |
$ 4 |
$14 |
$4 |
224 |
$0.1 |
-$5.8 |
0.7 |
0.1 |
| ORCHID BIOSCIENCES |
$0.42 |
15% |
-84% |
$23 |
$ 9 |
$14 |
$4 |
595 |
$0.0 |
-$89.1 |
0.1 |
0.1 |
| PARADIGM GENETICS |
$0.36 |
16% |
-78% |
$12 |
$ 9 |
$2 |
$4 |
253 |
$0.0 |
-$15.7 |
0.6 |
0.1 |
| RIGEL PHARMACEUTICALS |
$0.62 |
12% |
-84% |
$ 28 |
$37 |
-$8 |
$0 |
147 |
-$0.1 |
-$40.6 |
0.9 |
0.2 |
| SANGAMO BIOSCIENCES |
$2.71 |
28% |
-68% |
$ 67 |
$52 |
$15 |
$0 |
90 |
$0.2 |
-$83.8 |
0.6 |
0.5 |
| Genomic Targets Average |
. |
28% |
-67% |
$122 |
$104 |
$18 |
$14 |
. |
$0.0 |
-$49.2 |
2.3 |
0.4 |
| Genomic Targets Median |
. |
25% |
-71% |
$ 51 |
$52 |
$1 |
$1 |
. |
$0.0 |
-$36.7 |
1.1 |
0.3 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
02/28/03 Close
|
% 52wk High
|
% change from 02/28/02
|
Market Cap ($M)
|
Cash & Mkt. Sec. ($M)
|
Tech Value ($M)
|
LT Debt plus Convert
|
# of Staff
|
Tech Value / Staff ($M)
|
Est. Burn Rate ($M)
|
Survival Index (Yrs)
|
Equity Multiple
|
| EMBREX |
$6.66 |
26% |
-63% |
$ 54 |
$ 8 |
$46 |
$0 |
221 |
$0.2 |
na |
na |
0.9 |
| IDEXX LABORATORIES |
$36.46 |
96% |
40% |
$1,254 |
$128 |
$1,126 |
$0 |
2170 |
$0.5 |
na |
na |
3.8 |
| IMMUCELL CORP |
$1.95 |
56% |
-42% |
$ 5 |
$ 2 |
$4 |
$0 |
30 |
$0.1 |
na |
na |
0.6 |
| Agbio/enviro. Average |
. |
59% |
-22% |
$438 |
$46 |
$392 |
$0 |
. |
$0.3 |
na |
na |
1.7 |
| Agbio/enviro. Median |
. |
76% |
-1% |
$ 30 |
$ 5 |
$25 |
$0 |
. |
$0.4 |
na |
na |
0.9 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
02/28/03 Close
|
% 52wk High
|
% change from 02/28/02
|
Market Cap ($M)
|
Cash & Mkt. Sec. ($M)
|
Tech Value ($M)
|
LT Debt plus Convert
|
# of Staff
|
Tech Value / Staff ($M)
|
Est. Burn Rate ($M)
|
Survival Index (Yrs)
|
Equity Multiple
|
| ALEXION PHARMACEUTICALS |
$11.01 |
41% |
-49% |
$200 |
$283 |
-$83 |
$124 |
140 |
-$0.6 |
-$86.6 |
3.3 |
0.5 |
| AUTOIMMUNE |
$0.76 |
60% |
-28% |
$13 |
$10 |
$3 |
$0 |
na |
na |
-$1.0 |
10.4 |
0.1 |
| BIOMARIN PHARMACEUTICAL |
$10.01 |
91% |
0% |
$614 |
$86 |
$527 |
$0 |
216 |
$2.4 |
-$68.5 |
1.3 |
1.9 |
| CONNETICS CORP |
$14.65 |
96% |
34% |
$455 |
$29 |
$426 |
$0 |
162 |
$2.6 |
-$10.0 |
3.0 |
2.7 |
| CORTECH |
$2.51 |
61% |
-32% |
$ 9 |
$0 |
$9 |
$0 |
na |
na |
na |
na |
na |
| CYPRESS BIOSCIENCE |
$2.68 |
60% |
-21% |
$ 35 |
$14 |
$21 |
$0 |
9 |
$2.4 |
-$7.2 |
1.9 |
0.3 |
| EPIMMUNE |
$0.85 |
28% |
-70% |
$10 |
$12 |
-$2 |
$0 |
52 |
$0.0 |
-$6.0 |
2.0 |
0.1 |
| ICOS CORP |
$19.95 |
38% |
-53% |
$1,238 |
$85 |
$1,153 |
$0 |
469 |
$2.5 |
-$138.1 |
0.6 |
1.6 |
| INKINE PHARMACEUTICAL CO |
$1.59 |
64% |
22% |
$ 56 |
$ 7 |
$48 |
$0 |
12 |
$4.0 |
-$5.9 |
1.3 |
1.0 |
| KERYX BIOPHARMACEUTICALS |
$1.55 |
26% |
-67% |
$31 |
$27 |
$4 |
$0 |
63 |
$0.1 |
-$12.1 |
2.2 |
0.4 |
| LA JOLLA PHARMACEUTICAL CO |
$1.30 |
15% |
-79% |
$ 55 |
$65 |
-$10 |
$0 |
118 |
-$0.1 |
-$42.7 |
1.5 |
0.3 |
| PROTEIN DESIGN LABS |
$7.65 |
37% |
-52% |
$681 |
$624 |
$58 |
$159 |
363 |
$0.2 |
-$32.0 |
19.5 |
1.1 |
| TANOX |
$8.84 |
55% |
-36% |
$392 |
$235 |
$157 |
$5 |
114 |
$1.4 |
-$30.6 |
7.7 |
1.3 |
| Autoimmune Average |
. |
52% |
-33% |
$292 |
$114 |
$178 |
$22 |
. |
$1.3 |
-$36.7 |
4.5 |
0.9 |
| Autoimmune Median |
. |
57% |
-34% |
$ 56 |
$28 |
$15 |
$0 |
. |
$1.2 |
-$12.1 |
2.0 |
1.0 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
02/28/03 Close
|
% 52wk High
|
% change from 02/28/02
|
Market Cap ($M)
|
Cash & Mkt. Sec. ($M)
|
Tech Value ($M)
|
LT Debt plus Convert
|
# of Staff
|
Tech Value / Staff ($M)
|
Est. Burn Rate ($M)
|
Survival Index (Yrs)
|
Equity Multiple
|
| ALLOS THERAPEUTICS |
$4.40 |
44% |
-27% |
$113 |
$60 |
$53 |
$0 |
61 |
$0.9 |
-$21.2 |
2.8 |
0.7 |
| ANTIGENICS |
$8.13 |
54% |
-38% |
$269 |
$70 |
$198 |
$0 |
208 |
$1.0 |
-$54.2 |
1.3 |
0.9 |
| APHTON CORP |
$2.50 |
21% |
-78% |
$ 57 |
$ 9 |
$48 |
$0 |
50 |
$1.0 |
-$43.7 |
0.2 |
0.5 |
| AVAX TECHNOLOGIES |
$0.13 |
19% |
-75% |
$ 2 |
$ 6 |
-$4 |
$0 |
43 |
-$0.1 |
-$10.4 |
0.6 |
0.0 |
| AVI BIOPHARMA |
$3.16 |
28% |
-66% |
$ 84 |
$22 |
$61 |
$0 |
85 |
$0.7 |
-$28.2 |
0.8 |
0.6 |
| BIOMIRA |
$1.09 |
26% |
-71% |
$ 58 |
$83 |
-$25 |
$0 |
179 |
-$0.1 |
-$17.6 |
4.7 |
0.6 |
| BOSTON LIFE SCIENCES |
$0.93 |
32% |
-62% |
$21 |
$0 |
$21 |
$0 |
na |
na |
na |
na |
na |
| BRITISH BIOTECH PLC |
$2.19 |
24% |
-73% |
$37 |
$173 |
-$136 |
$3 |
145 |
-$0.9 |
-$36.2 |
4.8 |
0.1 |
| CELGENE CORP |
$21.90 |
79% |
-16% |
$1,724 |
$289 |
$1,435 |
$0 |
383 |
$3.7 |
-$4.1 |
69.7 |
3.2 |
| CELL PATHWAYS |
$0.81 |
14% |
-82% |
$ 32 |
$17 |
$15 |
$0 |
77 |
$0.2 |
-$18.9 |
0.9 |
0.2 |
| CELL THERAPEUTICS |
$7.02 |
26% |
-68% |
$229 |
$169 |
$60 |
$0 |
238 |
$0.3 |
-$121.6 |
1.4 |
0.6 |
| CORIXA CORP |
$5.99 |
53% |
-39% |
$301 |
$47 |
$254 |
$23 |
496 |
$0.5 |
-$66.3 |
0.7 |
0.2 |
| CYTOGEN CORP |
$2.87 |
11% |
-87% |
$25 |
$16 |
$9 |
$3 |
74 |
$0.1 |
-$15.9 |
1.0 |
0.1 |
| DENDREON |
$4.10 |
57% |
26% |
$108 |
$55 |
$53 |
$0 |
72 |
$0.7 |
-$20.8 |
2.6 |
0.7 |
| DOR BIOPHARMA |
$1.05 |
61% |
-19% |
$ 23 |
$ 4 |
$19 |
$0 |
22 |
$0.8 |
-$2.5 |
1.6 |
0.3 |
| DUSA PHARMACEUTICALS |
$1.52 |
29% |
-61% |
$ 21 |
$56 |
-$35 |
$2 |
55 |
-$0.6 |
na |
na |
0.2 |
| ENTREMED |
$1.04 |
11% |
-86% |
$ 23 |
$ 5 |
$18 |
$3 |
112 |
$0.2 |
-$47.0 |
0.1 |
0.1 |
| EXEGENICS |
$0.59 |
29% |
-65% |
$ 10 |
$20 |
-$10 |
$0 |
29 |
-$0.4 |
-$10.7 |
1.9 |
0.1 |
| GENAERA |
$0.32 |
9% |
-89% |
$ 11 |
$12 |
-$1 |
$0 |
57 |
$0.0 |
-$11.9 |
1.0 |
0.1 |
| GENTA |
$6.55 |
35% |
-49% |
$479 |
$127 |
$352 |
$10 |
60 |
$5.9 |
-$60.4 |
2.1 |
1.5 |
| GERON CORP |
$1.69 |
19% |
-77% |
$ 42 |
$47 |
-$6 |
$16 |
142 |
$0.0 |
-$28.8 |
1.6 |
0.2 |
| ILEX ONCOLOGY |
$6.34 |
34% |
-58% |
$206 |
$149 |
$57 |
$0 |
310 |
$0.2 |
-$41.6 |
3.6 |
0.4 |
| IMCLONE SYSTEMS |
$13.33 |
44% |
-41% |
$982 |
$293 |
$688 |
$242 |
399 |
$1.7 |
-$168.0 |
1.7 |
2.8 |
| IMMUNOGEN |
$2.37 |
20% |
-79% |
$103 |
$127 |
-$25 |
$0 |
105 |
-$0.2 |
-$12.9 |
9.9 |
0.3 |
| IMMUNOMEDICS |
$2.80 |
13% |
-83% |
$140 |
$38 |
$101 |
$0 |
94 |
$1.1 |
-$11.5 |
3.3 |
0.9 |
| MAXIM PHARMACEUTICALS |
$3.30 |
48% |
-41% |
$ 77 |
$108 |
-$31 |
$2 |
132 |
-$0.2 |
-$44.4 |
2.4 |
0.2 |
| MEDAREX |
$2.79 |
15% |
-82% |
$213 |
$370 |
-$157 |
$175 |
297 |
-$0.5 |
-$216.5 |
1.7 |
0.3 |
| NAPRO BIOTHERAPEUTICS |
$0.45 |
4% |
-96% |
$13 |
$12 |
$2 |
$25 |
189 |
$0.0 |
-$15.8 |
0.7 |
0.1 |
| NEOPHARM |
$10.76 |
43% |
-37% |
$176 |
$102 |
$74 |
$0 |
72 |
$1.0 |
-$41.1 |
2.5 |
1.0 |
| NEORX CORP |
$0.49 |
12% |
-88% |
$ 13 |
$12 |
$1 |
$5 |
118 |
$0.0 |
-$46.0 |
0.3 |
0.1 |
| OSI PHARMACEUTICALS |
$14.78 |
34% |
-61% |
$539 |
$465 |
$74 |
$160 |
429 |
$0.2 |
-$88.6 |
5.2 |
0.8 |
| OXIGENE |
$1.61 |
50% |
-25% |
$ 20 |
$14 |
$6 |
$0 |
15 |
$0.4 |
-$6.7 |
2.1 |
0.2 |
| PRAECIS PHARMACEUTICALS |
$4.05 |
69% |
-10% |
$210 |
$209 |
$1 |
$33 |
na |
na |
-$22.3 |
9.4 |
0.6 |
| PROGENICS PHARMACEUTICALS |
$5.40 |
32% |
-59% |
$ 68 |
$42 |
$27 |
$0 |
80 |
$0.3 |
-$25.6 |
1.6 |
0.7 |
| QLT PHOTOTHERAPEUTICS |
$9.09 |
43% |
-49% |
$621 |
$257 |
$363 |
$0 |
285 |
$1.3 |
-$48.3 |
5.3 |
1.3 |
| SCICLONE PHARMACEUTICALS |
$4.75 |
95% |
107% |
$175 |
$25 |
$151 |
$6 |
na |
na |
-$6.7 |
3.7 |
1.1 |
| SEATTLE GENETICS |
$2.87 |
43% |
-40% |
$ 88 |
$31 |
$57 |
$0 |
na |
na |
-$20.4 |
1.5 |
0.8 |
| XENOVA GROUP PLC |
$3.25 |
33% |
-66% |
$ 45 |
$18 |
$27 |
$0 |
134 |
$0.2 |
-$8.8 |
2.1 |
2.5 |
| Cancer Average |
. |
35% |
-53% |
$194 |
$94 |
$100 |
$19 |
. |
$0.6 |
-$40.1 |
4.4 |
0.7 |
| Cancer Median |
. |
32% |
-61% |
$ 77 |
$47 |
$21 |
$0 |
. |
$0.2 |
-$22.3 |
1.7 |
0.5 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
02/28/03 Close
|
% 52wk High
|
% change from 02/28/02
|
Market Cap ($M)
|
Cash & Mkt. Sec. ($M)
|
Tech Value ($M)
|
LT Debt plus Convert
|
# of Staff
|
Tech Value / Staff ($M)
|
Est. Burn Rate ($M)
|
Survival Index (Yrs)
|
Equity Multiple
|
| ATHEROGENICS |
$8.60 |
96% |
31% |
$313 |
$41 |
$272 |
$0 |
79 |
$3.4 |
-$27.7 |
1.5 |
2.6 |
| CORVAS INTERNATIONAL |
$1.74 |
26% |
-70% |
$ 48 |
$71 |
-$23 |
$12 |
95 |
-$0.2 |
-$26.2 |
2.7 |
0.2 |
| CV THERAPEUTICS |
$17.64 |
39% |
-54% |
$478 |
$420 |
$58 |
$196 |
222 |
$0.3 |
-$99.3 |
4.2 |
0.9 |
| QUESTCOR PHARMACEUTICALS |
$1.08 |
52% |
-29% |
$ 42 |
$ 9 |
$32 |
$3 |
38 |
$0.9 |
-$4.0 |
2.3 |
0.5 |
| SCIOS |
$43.64 |
99% |
118% |
$2,048 |
$66 |
$1,982 |
$161 |
425 |
$4.7 |
-$87.3 |
0.8 |
3.6 |
| TEXAS BIOTECHNOLOGY CORP |
$0.80 |
12% |
-86% |
$35 |
$47 |
-$12 |
$0 |
na |
na |
-$23.4 |
2.0 |
0.2 |
| Cardiovascular Average |
. |
54% |
-15% |
$494 |
$109 |
$385 |
$62 |
. |
$1.8 |
-$44.6 |
2.3 |
1.3 |
| Cardiovascular Median |
. |
52% |
-29% |
$ 48 |
$47 |
$32 |
$3 |
. |
$0.9 |
-$26.2 |
2.0 |
0.9 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
02/28/03 Close
|
% 52wk High
|
% change from 02/28/02
|
Market Cap ($M)
|
Cash & Mkt. Sec. ($M)
|
Tech Value ($M)
|
LT Debt plus Convert
|
# of Staff
|
Tech Value / Staff ($M)
|
Est. Burn Rate ($M)
|
Survival Index (Yrs)
|
Equity Multiple
|
| 3-DIMENSIONAL PHARMACEUTICALS |
$5.71 |
75% |
-23% |
$129 |
$75 |
$54 |
$5 |
204 |
$0.3 |
-$30.8 |
2.4 |
0.8 |
| ARGONAUT TECHNOLOGIES |
$0.97 |
31% |
-61% |
$19 |
$29 |
-$9 |
$0 |
154 |
-$0.1 |
-$21.4 |
1.3 |
0.2 |
| ARIAD PHARMACEUTICALS |
$1.79 |
29% |
-53% |
$ 62 |
$28 |
$34 |
$6 |
69 |
$0.5 |
-$31.3 |
0.9 |
0.4 |
| ARQULE |
$2.37 |
18% |
-81% |
$ 51 |
$83 |
-$32 |
$8 |
385 |
-$0.1 |
-$21.9 |
3.8 |
0.2 |
| ARRAY BIOPHARMA |
$4.08 |
31% |
-60% |
$114 |
$52 |
$62 |
$0 |
na |
na |
-$4.9 |
10.7 |
0.9 |
| BIOCRYST PHARMACEUTICALS |
$1.01 |
21% |
-76% |
$ 18 |
$27 |
-$9 |
$0 |
77 |
-$0.1 |
-$13.7 |
2.0 |
0.1 |
| KOSAN BIOSCIENCES |
$5.50 |
59% |
-23% |
$140 |
$63 |
$76 |
$0 |
68 |
$1.1 |
-$29.5 |
2.1 |
1.0 |
| PHARMACOPEIA |
$6.60 |
43% |
-47% |
$155 |
$142 |
$13 |
$0 |
800 |
$0.0 |
-$25.3 |
5.6 |
0.5 |
| SYMYX TECHNOLOGIES |
$13.26 |
53% |
-21% |
$409 |
$119 |
$290 |
$0 |
204 |
$1.4 |
na |
na |
2.7 |
| VERTEX PHARMACEUTICALS |
$11.05 |
34% |
-49% |
$841 |
$651 |
$190 |
$315 |
1000 |
$0.2 |
-$133.8 |
4.9 |
1.1 |
| Chemistry Average |
. |
39% |
-49% |
$194 |
$127 |
$67 |
$33 |
. |
$0.4 |
-$34.7 |
3.8 |
0.8 |
| Chemistry Median |
. |
34% |
-49% |
$114 |
$63 |
$34 |
$0 |
. |
$0.2 |
-$23.6 |
2.3 |
0.8 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
02/28/03 Close
|
% 52wk High
|
% change from 02/28/02
|
Market Cap ($M)
|
Cash & Mkt. Sec. ($M)
|
Tech Value ($M)
|
LT Debt plus Convert
|
# of Staff
|
Tech Value / Staff ($M)
|
Est. Burn Rate ($M)
|
Survival Index (Yrs)
|
Equity Multiple
|
| CEPHALON |
$48.15 |
70% |
-17% |
$2,657 |
$637 |
$2,020 |
$871 |
1127 |
$1.8 |
na |
na |
2.7 |
| DOV PHARMACEUTICALS |
$5.64 |
47% |
na |
$ 81 |
$64 |
$17 |
$14 |
NA |
NA |
-$10.4 |
6.2 |
1.0 |
| GUILFORD PHARMACEUTICALS |
$3.43 |
33% |
-60% |
$102 |
$96 |
$7 |
$4 |
289 |
$0.0 |
-$58.3 |
1.6 |
0.3 |
| INDEVUS PHARMACEUTICALS |
$2.06 |
22% |
-75% |
$97 |
$40 |
$56 |
$0 |
19 |
$3.0 |
-$19.3 |
2.1 |
0.3 |
| MACROCHEM CORP |
$0.61 |
18% |
-80% |
$ 17 |
$10 |
$7 |
$0 |
32 |
$0.2 |
-$6.1 |
1.7 |
0.2 |
| NEUROCRINE BIOSCIENCES |
$42.13 |
84% |
19% |
$1,289 |
$275 |
$1,014 |
$0 |
222 |
$4.6 |
-$80.9 |
3.4 |
3.1 |
| SPECTRUM PHARMACEUTICALS |
$1.98 |
3% |
-97% |
$ 3 |
$ 0 |
$3 |
$0 |
53 |
$0.1 |
-$9.4 |
0.0 |
0.0 |
| SYNAPTIC PHARMACEUTICAL CORP |
$6.46 |
94% |
4% |
$ 71 |
$28 |
$43 |
$0 |
101 |
$0.4 |
-$32.5 |
0.9 |
0.5 |
| TITAN PHARMACEUTICALS |
$1.55 |
19% |
-76% |
$ 43 |
$81 |
-$39 |
$0 |
58 |
-$0.7 |
-$29.2 |
2.8 |
0.2 |
| CNS Average |
. |
43% |
-48% |
$485 |
$137 |
$348 |
$99 |
. |
$1.2 |
-$30.8 |
2.3 |
0.9 |
| CNS Median |
. |
40% |
-60% |
$76 |
$52 |
$12 |
$0 |
. |
$0.4 |
-$19.3 |
1.7 |
0.4 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
02/28/03 Close
|
% 52wk High
|
% change from 02/28/02
|
Market Cap ($M)
|
Cash & Mkt. Sec. ($M)
|
Tech Value ($M)
|
LT Debt plus Convert
|
# of Staff
|
Tech Value / Staff ($M)
|
Est. Burn Rate ($M)
|
Survival Index (Yrs)
|
Equity Multiple
|
| ABGENIX |
$5.76 |
26% |
-68% |
$504 |
$464 |
$41 |
$200 |
324 |
$0.1 |
-$135.4 |
3.4 |
0.5 |
| ALKERMES |
$7.94 |
25% |
-68% |
$512 |
$72 |
$440 |
$206 |
520 |
$0.8 |
-$271.4 |
0.3 |
1.1 |
| ARADIGM CORP |
$0.79 |
14% |
-80% |
$ 25 |
$35 |
-$11 |
$0 |
307 |
$0.0 |
-$41.1 |
0.9 |
0.1 |
| BIODELIVERY SCIENCES |
$2.19 |
58% |
na |
$16 |
$ 6 |
$9 |
$0 |
8 |
$1.1 |
-$5.7 |
1.1 |
1.1 |
| CIMA LABS |
$20.49 |
70% |
-11% |
$292 |
$73 |
$218 |
$0 |
171 |
$1.3 |
na |
na |
1.2 |
| CYGNUS |
$0.40 |
6% |
-90% |
$15 |
$25 |
-$10 |
$20 |
102 |
-$0.1 |
-$40.8 |
0.6 |
0.1 |
| DEPOMED |
$2.34 |
44% |
-55% |
$ 33 |
$ 9 |
$24 |
$0 |
40 |
$0.6 |
-$35.4 |
0.3 |
0.5 |
| EMISPHERE TECHNOLOGIES |
$5.62 |
28% |
-64% |
$101 |
$18 |
$83 |
$32 |
241 |
$0.3 |
-$52.1 |
0.3 |
0.3 |
| ENZON PHARMACEUTICALS |
$12.55 |
26% |
-71% |
$545 |
$224 |
$321 |
$0 |
106 |
$3.0 |
na |
na |
2.1 |
| FLAMEL TECHNOLOGIES SA |
$4.72 |
87% |
120% |
$ 76 |
$13 |
$64 |
$2 |
137 |
$0.5 |
-$8.9 |
1.5 |
1.5 |
| GENETRONICS BIOMEDICAL LTD |
$0.35 |
52% |
-33% |
$18 |
$ 2 |
$15 |
$0 |
27 |
$0.6 |
-$5.6 |
0.4 |
0.3 |
| NEKTAR THERAPEUTICS |
$5.05 |
38% |
-61% |
$280 |
$314 |
-$34 |
$299 |
694 |
$0.0 |
-$106.1 |
3.0 |
0.4 |
| NOVAVAX |
$4.25 |
35% |
-59% |
$105 |
$8 |
$97 |
$40 |
173 |
$0.6 |
-$26.9 |
0.3 |
1.0 |
| NOVEN PHARMACEUTICALS |
$10.86 |
39% |
-48% |
$245 |
$60 |
$185 |
$0 |
252 |
$0.7 |
na |
na |
3.1 |
| SEPRACOR |
$12.36 |
26% |
-71% |
$1,040 |
$553 |
$487 |
$999 |
930 |
$0.5 |
-$94.4 |
5.9 |
1.3 |
| SHEFFIELD PHARMACEUTICALS |
$0.27 |
9% |
-91% |
$ 8 |
$ 0 |
$8 |
$12 |
16 |
$0.5 |
-$5.2 |
0.1 |
0.1 |
| Delivery Average |
. |
37% |
-50% |
$238 |
$117 |
$121 |
$113 |
. |
$0.7 |
-$63.8 |
1.4 |
0.9 |
| Delivery Median |
. |
35% |
-62% |
$101 |
$25 |
$41 |
$2 |
. |
$0.6 |
-$38.1 |
0.7 |
1.0 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
02/28/03 Close
|
% 52wk High
|
% change from 02/28/02
|
Market Cap ($M)
|
Cash & Mkt. Sec. ($M)
|
Tech Value ($M)
|
LT Debt plus Convert
|
# of Staff
|
Tech Value / Staff ($M)
|
Est. Burn Rate ($M)
|
Survival Index (Yrs)
|
Equity Multiple
|
| ADVANCED MAGNETICS |
$4.20 |
79% |
17% |
$28 |
$18 |
$10 |
$0 |
24 |
$0.4 |
-$9.5 |
1.8 |
0.6 |
| CHOLESTECH CORP |
$6.36 |
32% |
-44% |
$ 87 |
$15 |
$72 |
$0 |
220 |
$0.3 |
na |
na |
1.1 |
| DIAGNOSTIC PRODUCTS CORP |
$33.91 |
64% |
-5% |
$968 |
$43 |
$925 |
$0 |
1955 |
$0.5 |
na |
na |
16.6 |
| DIGENE CORP |
$16.59 |
44% |
-48% |
$301 |
$34 |
$267 |
$3 |
243 |
$1.1 |
-$10.5 |
3.2 |
2.6 |
| ENZO BIOCHEM |
$12.36 |
58% |
-32% |
$352 |
$73 |
$279 |
$0 |
255 |
$1.1 |
na |
na |
2.2 |
| EPIX MEDICAL |
$6.40 |
40% |
-50% |
$109 |
$36 |
$73 |
$0 |
88 |
$0.8 |
-$22.4 |
1.6 |
0.9 |
| HYCOR BIOMEDICAL |
$2.38 |
43% |
-56% |
$ 19 |
$ 6 |
$14 |
$1 |
149 |
$0.1 |
na |
na |
1.5 |
| IGEN INTERNATIONAL |
$32.96 |
72% |
-21% |
$783 |
$49 |
$733 |
$46 |
370 |
$2.0 |
-$33.4 |
1.5 |
3.2 |
| LUMINEX |
$4.00 |
28% |
-73% |
$118 |
$40 |
$78 |
$0 |
183 |
$0.4 |
-$22.1 |
1.8 |
1.0 |
| MARTEK BIOSCIENCES CORP |
$24.40 |
71% |
-9% |
$570 |
$29 |
$541 |
$0 |
166 |
$3.3 |
-$15.0 |
1.9 |
2.4 |
| MATRITECH |
$1.80 |
55% |
-22% |
$ 55 |
$ 3 |
$53 |
$0 |
44 |
$1.2 |
-$8.5 |
0.3 |
0.8 |
| ORASURE |
$6.82 |
79% |
31% |
$256 |
$13 |
$243 |
$3 |
221 |
$1.1 |
-$1.5 |
8.6 |
1.7 |
| OSTEX INTERNATIONAL |
$1.94 |
72% |
-10% |
$ 24 |
$1 |
$23 |
$1 |
46 |
$0.5 |
-$4.5 |
0.2 |
0.5 |
| QUIDEL CORP |
$3.15 |
44% |
-50% |
$ 91 |
$ 5 |
$86 |
$0 |
336 |
$0.3 |
-$4.8 |
1.0 |
0.6 |
| SONUS PHARMACEUTICALS |
$2.20 |
31% |
-60% |
$ 30 |
$19 |
$11 |
$0 |
34 |
$0.3 |
-$13.1 |
1.5 |
0.5 |
| TRINITY BIOTECH PLC |
$1.95 |
99% |
26% |
$ 79 |
$ 1 |
$78 |
$0 |
332 |
$0.2 |
na |
na |
3.6 |
| Diagnostic/imag. Average |
. |
57% |
-25% |
$242 |
$24 |
$218 |
$3 |
. |
$0.9 |
-$13.2 |
2.1 |
2.5 |
| Diagnostic/imag. Median |
. |
58% |
-22% |
$ 91 |
$18 |
$78 |
$0 |
. |
$0.5 |
-$10.0 |
1.6 |
1.1 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
02/28/03 Close
|
% 52wk High
|
% change from 02/28/02
|
Market Cap ($M)
|
Cash & Mkt. Sec. ($M)
|
Tech Value ($M)
|
LT Debt plus Convert
|
# of Staff
|
Tech Value / Staff ($M)
|
Est. Burn Rate ($M)
|
Survival Index (Yrs)
|
Equity Multiple
|
| AASTROM BIOSCIENCES |
$0.30 |
34% |
-66% |
$15 |
$8 |
$8 |
$0 |
44 |
$0.2 |
-$9.8 |
0.8 |
0.1 |
| AVIGEN |
$2.90 |
25% |
-65% |
$ 58 |
$125 |
-$67 |
$0 |
143 |
-$0.5 |
-$28.4 |
4.4 |
0.2 |
| CELL GENESYS |
$7.94 |
44% |
-47% |
$286 |
$226 |
$60 |
$0 |
262 |
$0.2 |
-$50.8 |
4.4 |
1.0 |
| DIACRIN |
$1.03 |
46% |
-51% |
$ 18 |
$40 |
-$22 |
$0 |
30 |
-$0.7 |
-$6.1 |
6.5 |
0.2 |
| INTROGEN |
$2.19 |
41% |
-52% |
$47 |
$31 |
$16 |
$7 |
77 |
$0.2 |
-$22.8 |
1.4 |
0.5 |
| RIBOZYME PHARMACEUTICALS |
$0.34 |
9% |
-88% |
$ 7 |
$15 |
-$8 |
$5 |
130 |
-$0.1 |
-$27.3 |
0.6 |
0.0 |
| TARGETED GENETICS CORP |
$0.29 |
13% |
-86% |
$ 15 |
$17 |
-$3 |
$23 |
173 |
$0.0 |
-$19.3 |
0.9 |
0.1 |
| TRANSGENE SA |
$1.52 |
53% |
-35% |
$ 46 |
na |
na |
$0 |
318 |
na |
na |
na |
na |
| TRANSKARYOTIC THERAPIES |
$5.01 |
11% |
-87% |
$175 |
$288 |
-$114 |
$0 |
376 |
-$0.3 |
-$83.6 |
3.5 |
0.3 |
| VALENTIS |
$4.95 |
5% |
-88% |
$ 6 |
$12 |
-$6 |
$0 |
58 |
-$0.1 |
-$18.6 |
0.6 |
0.0 |
| VICAL |
$2.53 |
25% |
-70% |
$ 51 |
$120 |
-$69 |
$0 |
152 |
-$0.5 |
-$40.9 |
2.9 |
0.2 |
| Gene therapy Average |
. |
28% |
-67% |
$ 66 |
$88 |
-$20 |
$3 |
. |
-$0.2 |
-$30.8 |
2.6 |
0.3 |
| Gene therapy Median |
. |
29% |
-66% |
$ 32 |
$31 |
-$6 |
$0 |
. |
-$0.1 |
-$22.8 |
1.4 |
0.2 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
02/28/03 Close
|
% 52wk High
|
% change from 02/28/02
|
Market Cap ($M)
|
Cash & Mkt. Sec. ($M)
|
Tech Value ($M)
|
LT Debt plus Convert
|
# of Staff
|
Tech Value / Staff ($M)
|
Est. Burn Rate ($M)
|
Survival Index (Yrs)
|
Equity Multiple
|
| AVANT IMMUNOTHERAPEUTICS |
$1.09 |
44% |
-19% |
$ 66 |
$26 |
$40 |
$0 |
71 |
$0.6 |
-$1.1 |
23.8 |
0.3 |
| ESSENTIAL |
$0.12 |
3% |
-96% |
$ 2 |
$41 |
-$38 |
$1 |
139 |
-$0.3 |
-$20.3 |
2.0 |
0.0 |
| GENELABS TECHNOLOGIES |
$1.33 |
37% |
-28% |
$ 71 |
$12 |
$59 |
$0 |
90 |
$0.7 |
-$17.2 |
0.7 |
0.4 |
| IMMUNE RESPONSE CORP |
$1.42 |
30% |
-62% |
$ 14 |
$1 |
$13 |
$3 |
129 |
$0.1 |
-$22.0 |
0.1 |
0.1 |
| INTERMUNE |
$19.96 |
52% |
-45% |
$631 |
$343 |
$288 |
$150 |
57 |
$5.1 |
-$39.0 |
8.8 |
1.3 |
| INTRABIOTICS |
$0.16 |
3% |
-95% |
$ 6 |
$35 |
-$29 |
$4 |
31 |
-$0.9 |
-$45.1 |
0.8 |
0.0 |
| MEDIMMUNE |
$30.01 |
67% |
-27% |
$7,540 |
$454 |
$7,086 |
$218 |
877 |
$8.1 |
-$145.2 |
3.1 |
2.9 |
| NABI BIOPHARMACEUTICALS |
$5.13 |
67% |
-7% |
$199 |
$44 |
$155 |
$0 |
615 |
$0.3 |
na |
na |
1.2 |
| NEOSE TECHNOLOGIES |
$6.24 |
19% |
-80% |
$89 |
$43 |
$46 |
$4 |
111 |
$0.4 |
-$23.8 |
1.8 |
0.5 |
| SIGA TECHNOLOGIES |
$1.26 |
46% |
-52% |
$14 |
$ 1 |
$13 |
$0 |
12 |
$1.1 |
-$2.5 |
0.4 |
0.5 |
| TRIMERIS |
$40.02 |
70% |
5% |
$854 |
$61 |
$793 |
$0 |
109 |
$7.3 |
-$72.6 |
0.8 |
3.0 |
| VAXGEN |
$3.76 |
16% |
-66% |
$ 54 |
$26 |
$28 |
$0 |
80 |
$0.4 |
-$31.0 |
0.8 |
0.4 |
| VERSICOR |
$10.30 |
51% |
-43% |
$272 |
$73 |
$199 |
$1 |
63 |
$3.2 |
-$52.1 |
1.4 |
1.3 |
| VION PHARMACEUTICALS |
$0.36 |
8% |
-91% |
$ 10 |
$13 |
-$3 |
$0 |
50 |
-$0.1 |
-$9.9 |
1.3 |
0.1 |
| VIROLOGIC |
$0.92 |
27% |
-61% |
$ 23 |
$ 6 |
$17 |
$0 |
204 |
$0.1 |
-$22.3 |
0.3 |
0.2 |
| VIROPHARMA |
$1.73 |
10% |
-89% |
$45 |
$176 |
-$131 |
$156 |
418 |
$0.4 |
na |
na |
0.2 |
| XOMA LTD |
$3.61 |
40% |
-55% |
$254 |
$36 |
$218 |
$58 |
193 |
$1.1 |
-$49.0 |
0.7 |
-18.5 |
| Infection Average |
. |
35% |
-54% |
$597 |
$82 |
$515 |
$35 |
. |
$1.6 |
-$36.9 |
3.1 |
-0.4 |
| Infection Median |
. |
39% |
-54% |
$ 60 |
$36 |
$34 |
$1 |
. |
$0.5 |
-$23.1 |
0.9 |
0.4 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
02/28/03 Close
|
% 52wk High
|
% change from 02/28/02
|
Market Cap ($M)
|
Cash & Mkt. Sec. ($M)
|
Tech Value ($M)
|
LT Debt plus Convert
|
# of Staff
|
Tech Value / Staff ($M)
|
Est. Burn Rate ($M)
|
Survival Index (Yrs)
|
Equity Multiple
|
| AMYLIN PHARMACEUTICALS |
$15.34 |
81% |
73% |
$1,256 |
$180 |
$1,076 |
$0 |
150 |
$7.2 |
-$125.2 |
1.4 |
2.4 |
| BIO-TECHNOLOGY GENERAL CORP |
$2.55 |
41% |
-52% |
$150 |
$20 |
$130 |
$14 |
378 |
$0.3 |
na |
na |
0.7 |
| INSMED INC |
$0.49 |
15% |
-82% |
$ 16 |
$ 0 |
$16 |
$0 |
na |
na |
-$2.2 |
0.0 |
9.6 |
| NPS PHARMACEUTICALS |
$17.36 |
48% |
-42% |
$529 |
$158 |
$371 |
$0 |
146 |
$2.5 |
-$73.1 |
2.2 |
1.4 |
| ZONAGEN |
$0.93 |
19% |
-80% |
$ 11 |
$27 |
-$17 |
$0 |
10 |
-$1.7 |
na |
na |
0.1 |
| Metabolic Average |
. |
41% |
-37% |
$392 |
$77 |
$315 |
$3 |
. |
$2.1 |
-$66.8 |
1.2 |
2.8 |
| Metabolic Median |
. |
44% |
-47% |
$ 83 |
$24 |
$73 |
$0 |
. |
$1.0 |
-$37.7 |
1.2 |
1.2 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
02/28/03 Close
|
% 52wk High
|
% change from 02/28/02
|
Market Cap ($M)
|
Cash & Mkt. Sec. ($M)
|
Tech Value ($M)
|
LT Debt plus Convert
|
# of Staff
|
Tech Value / Staff ($M)
|
Est. Burn Rate ($M)
|
Survival Index (Yrs)
|
Equity Multiple
|
| ALBANY MOLECULAR RESEARCH |
$14.50 |
48% |
-48% |
$470 |
$121 |
$349 |
$5 |
532 |
$0.7 |
na |
na |
2.6 |
| BIOPURE CORP |
$3.11 |
23% |
-55% |
$ 96 |
$30 |
$66 |
$10 |
211 |
$0.3 |
-$50.4 |
0.6 |
0.2 |
| BIORELIANCE CORP |
$17.00 |
61% |
-18% |
$144 |
$36 |
$108 |
$11 |
556 |
$0.2 |
na |
na |
2.6 |
| BIOTIME |
$1.59 |
41% |
-59% |
$ 21 |
$ 2 |
$20 |
$2 |
12 |
$1.6 |
-$2.3 |
0.8 |
0.7 |
| CARRINGTON LABORATORIES |
$1.03 |
40% |
-49% |
$10 |
$ 2 |
$8 |
$0 |
181 |
$0.0 |
-$2.2 |
1.1 |
0.2 |
| COLLAGENEX PHARMACEUTICALS |
$9.06 |
75% |
-9% |
$103 |
$ 5 |
$98 |
$0 |
155 |
$0.6 |
na |
na |
1.2 |
| COLUMBIA LABORATORIES |
$3.15 |
53% |
-17% |
$112 |
$ 4 |
$107 |
$10 |
19 |
$5.7 |
-$7.5 |
0.6 |
0.9 |
| CYANOTECH CORP |
$0.51 |
43% |
-54% |
$ 9 |
$ 0 |
$9 |
$3 |
53 |
$0.2 |
-$2.2 |
0.1 |
0.4 |
| CYTRX CORP |
$0.41 |
39% |
-38% |
$ 9 |
$ 2 |
$7 |
$0 |
5 |
$1.3 |
-$9.9 |
0.2 |
0.1 |
| DISCOVERY LABORATORIES |
$1.85 |
56% |
-40% |
$ 61 |
$11 |
$50 |
$0 |
50 |
$1.0 |
-$18.1 |
0.6 |
0.8 |
| GTC BIOTHERAPEUTICS |
$1.36 |
35% |
-61% |
$38 |
$66 |
-$28 |
$13 |
168 |
-$0.2 |
-$27.9 |
2.4 |
0.2 |
| ICON PLC |
$25.99 |
75% |
-16% |
$307 |
$0 |
$307 |
$0 |
1262 |
$0.2 |
na |
na |
na |
| IMMUCOR |
$19.73 |
76% |
187% |
$249 |
$ 6 |
$243 |
$23 |
481 |
$0.5 |
na |
na |
8.6 |
| INSITE VISION |
$0.80 |
36% |
-58% |
$ 20 |
$ 4 |
$17 |
$0 |
39 |
$0.4 |
-$12.4 |
0.3 |
0.2 |
| INVITROGEN CORP |
$31.04 |
79% |
-32% |
$1,601 |
$712 |
$889 |
$512 |
2726 |
$0.3 |
na |
na |
0.9 |
| MOLECULAR DEVICES CORP |
$13.16 |
62% |
-38% |
$202 |
$51 |
$150 |
$0 |
370 |
$0.4 |
na |
na |
1.1 |
| NORTHFIELD LABORATORIES |
$5.82 |
65% |
-23% |
$ 83 |
$12 |
$71 |
$0 |
60 |
$1.2 |
-$12.6 |
1.0 |
0.7 |
| OSTEOTECH |
$7.50 |
66% |
-10% |
$127 |
$19 |
$108 |
$17 |
365 |
$0.3 |
na |
na |
2.0 |
| PAIN THERAPEUTICS |
$1.85 |
15% |
-81% |
$ 50 |
$54 |
-$4 |
$0 |
26 |
-$0.1 |
-$12.2 |
4.4 |
0.5 |
| PHARMACEUTICAL PRODUCT DEVELOP |
$31.37 |
89% |
1% |
$1,743 |
$147 |
$1,596 |
$7 |
4375 |
$0.4 |
na |
na |
6.5 |
| PHARMACYCLICS |
$3.30 |
36% |
-54% |
$ 53 |
$109 |
-$56 |
$0 |
176 |
-$0.3 |
-$26.9 |
4.1 |
0.2 |
| PHARMOS CORP |
$0.98 |
49% |
-46% |
$ 55 |
$25 |
$30 |
$0 |
70 |
$0.4 |
-$21.8 |
1.2 |
0.5 |
| QIAGEN NV |
$5.84 |
34% |
-62% |
$849 |
$30 |
$819 |
$0 |
na |
na |
na |
na |
17.1 |
| QUINTILES TRANSNATIONAL CORP |
$12.40 |
64% |
-25% |
$1,461 |
$ 1 |
$1,461 |
$0 |
17224 |
$0.1 |
na |
na |
na |
| SANGSTAT MEDICAL CORP |
$8.37 |
30% |
-60% |
$221 |
$107 |
$114 |
$15 |
263 |
$0.4 |
na |
na |
0.7 |
| SICOR |
$14.84 |
78% |
-7% |
$1,737 |
$201 |
$1,536 |
$25 |
1851 |
$0.8 |
na |
na |
2.2 |
| SUPERGEN |
$3.38 |
39% |
-61% |
$111 |
$27 |
$84 |
$0 |
115 |
$0.7 |
-$80.4 |
0.3 |
0.4 |
| TRIPOS |
$5.30 |
20% |
-76% |
$ 47 |
$10 |
$36 |
$3 |
267 |
$0.1 |
-$3.1 |
3.3 |
1.3 |
| Other Average |
. |
51% |
-32% |
$357 |
$64 |
$293 |
$23 |
. |
$0.6 |
-$19.3 |
1.4 |
2.0 |
| Other Median |
. |
49% |
-40% |
$103 |
$19 |
$84 |
$1 |
. |
$0.4 |
-$12.3 |
0.9 |
0.8 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
02/28/03 Close
|
% 52wk High
|
% change from 02/28/02
|
Market Cap ($M)
|
Cash & Mkt. Sec. ($M)
|
Tech Value ($M)
|
LT Debt plus Convert
|
# of Staff
|
Tech Value / Staff ($M)
|
Est. Burn Rate ($M)
|
Survival Index (Yrs)
|
Equity Multiple
|
| AMGEN |
$54.64 |
87% |
-6% |
$70,325 |
$4,042 |
$66,283 |
$3,040 |
7700 |
$8.6 |
na |
na |
3.7 |
| BIOGEN |
$35.54 |
62% |
-33% |
$5,298 |
$828 |
$4,469 |
$39 |
1992 |
$2.2 |
na |
na |
6.4 |
| CHIRON CORP |
$36.52 |
74% |
-16% |
$6,870 |
$945 |
$5,925 |
$415 |
3736 |
$1.6 |
na |
na |
2.8 |
| GENENTECH |
$35.36 |
65% |
-25% |
$18,125 |
$1,124 |
$17,001 |
$0 |
4950 |
$3.4 |
na |
na |
2.7 |
| GENZYME CORP |
$31.18 |
60% |
-30% |
$6,690 |
$441 |
$6,249 |
$869 |
5200 |
$1.2 |
na |
na |
2.4 |
| GILEAD SCIENCES |
$34.00 |
85% |
-3% |
$6,687 |
$625 |
$6,062 |
$250 |
1000 |
$6.1 |
na |
na |
7.1 |
| IDEC PHARMACEUTICALS CORP |
$28.75 |
40% |
-54% |
$4,400 |
$947 |
$3,452 |
$861 |
692 |
$5.0 |
na |
na |
4.9 |
| Revenue-driven Average |
. |
67% |
-24% |
$16,914 |
$1,279 |
$15,635 |
$782 |
. |
$4.0 |
na |
na |
4.3 |
| Revenue-driven Median |
. |
69% |
-20% |
$6,689 |
$887 |
$5,994 |
$333 |
. |
$2.8 |
na |
na |
3.2 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
02/28/03 Close
|
% 52wk High
|
% change from 02/28/02
|
Market Cap ($M)
|
Cash & Mkt. Sec. ($M)
|
Tech Value ($M)
|
LT Debt plus Convert
|
# of Staff
|
Tech Value / Staff ($M)
|
Est. Burn Rate ($M)
|
Survival Index (Yrs)
|
Equity Multiple
|
| CUBIST PHARMACEUTICALS |
$8.22 |
36% |
-42% |
$235 |
$147 |
$88 |
$209 |
180 |
$0.5 |
-$68.0 |
2.2 |
0.9 |
| DISCOVERY PARTNERS |
$2.59 |
32% |
-57% |
$ 63 |
$70 |
-$7 |
$0 |
225 |
$0.0 |
-$3.2 |
21.6 |
0.3 |
| DIVERSA |
$7.01 |
51% |
-35% |
$251 |
$164 |
$87 |
$11 |
276 |
$0.3 |
-$26.8 |
6.1 |
0.9 |
| DYAX |
$1.72 |
33% |
-65% |
$ 34 |
$34 |
$0 |
$16 |
239 |
$0.0 |
-$22.7 |
1.5 |
0.2 |
| ISIS PHARMACEUTICALS |
$4.48 |
25% |
-69% |
$247 |
$292 |
-$45 |
$179 |
434 |
-$0.1 |
-$70.3 |
4.2 |
0.4 |
| LIGAND PHARMACEUTICALS |
$4.73 |
23% |
-67% |
$338 |
$35 |
$303 |
$4 |
351 |
$0.9 |
-$28.2 |
1.3 |
0.5 |
| NEUROGEN CORP |
$3.78 |
26% |
-72% |
$ 68 |
$84 |
-$16 |
$20 |
200 |
-$0.1 |
-$31.2 |
2.7 |
0.4 |
| ONYX PHARMACEUTICALS |
$7.20 |
80% |
87% |
$155 |
$50 |
$105 |
$5 |
85 |
$1.2 |
-$43.3 |
1.2 |
0.8 |
| REGENERON PHARMACEUTICALS |
$18.34 |
68% |
-19% |
$808 |
$300 |
$508 |
$200 |
575 |
$0.9 |
-$131.3 |
2.3 |
1.4 |
| REPLIGEN CORP |
$3.47 |
77% |
20% |
$ 95 |
$17 |
$77 |
$0 |
40 |
$1.9 |
-$4.3 |
4.0 |
0.6 |
| TULARIK |
$4.01 |
18% |
-78% |
$220 |
$175 |
$45 |
$9 |
380 |
$0.1 |
-$91.8 |
1.9 |
0.6 |
| Screening Average |
. |
43% |
-36% |
$228 |
$124 |
$104 |
$59 |
. |
$0.5 |
-$47.4 |
4.4 |
0.6 |
| Screening Median |
. |
35% |
-49% |
$188 |
$77 |
$61 |
$10 |
. |
$0.4 |
-$29.7 |
2.2 |
0.6 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
02/28/03 Close
|
% 52wk High
|
% change from 02/28/02
|
Market Cap ($M)
|
Cash & Mkt. Sec. ($M)
|
Tech Value ($M)
|
LT Debt plus Convert
|
# of Staff
|
Tech Value / Staff ($M)
|
Est. Burn Rate ($M)
|
Survival Index (Yrs)
|
Equity Multiple
|
| CELLEGY PHARMACEUTICALS |
$4.16 |
59% |
-28% |
$ 81 |
$ 5 |
$76 |
$1 |
36 |
$2.1 |
-$6.5 |
0.8 |
0.9 |
| LIFECELL CORP |
$2.38 |
63% |
-16% |
$ 50 |
$ 5 |
$44 |
$1 |
138 |
$0.3 |
na |
na |
0.6 |
| LIFECORE BIOMEDICAL |
$7.25 |
62% |
-19% |
$ 93 |
$ 1 |
$93 |
$6 |
200 |
$0.5 |
-$4.2 |
0.2 |
2.0 |
| Wound Average |
. |
61% |
-21% |
$ 75 |
$ 4 |
$71 |
$2 |
. |
$1.0 |
-$5.3 |
0.5 |
1.2 |
| Wound Median |
. |
62% |
-18% |
$ 65 |
$ 3 |
$60 |
$1 |
. |
$0.7 |
-$4.2 |
0.8 |
0.9 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Grand Average |
. |
42% |
-44% |
$782 |
$143 |
$645 |
$57 |
. |
$0.8 |
-$39.0 |
2.8 |
1.1 |
| Grand Median |
. |
39% |
-52% |
$101 |
$47 |
$45 |
$0 |
. |
$0.4 |
-$27.5 |
1.7 |
0.6 |
originally published 03/06/2003 |